Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these drugs can be contraindicated for an estimated 16 million men living with diabetes  CF602’s unique mechanism of action enables potential treatment of diabetic patients  RAMAT GAN, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncologic ...